Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-α blocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-α blockers in AS, suggesting that bone destruction and bone proliferation might be prevented.
Keywords: Ankylosing spodylitis, biologic agents, TNF blockers, treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Treatment of Ankylosing Spondylitis with Biologic Agents
Volume: 9 Issue: 1
Author(s): Mehmet Tuncay Duruoz
Affiliation:
Keywords: Ankylosing spodylitis, biologic agents, TNF blockers, treatment
Abstract: Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-α blocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-α blockers in AS, suggesting that bone destruction and bone proliferation might be prevented.
Export Options
About this article
Cite this article as:
Duruoz Tuncay Mehmet, Treatment of Ankylosing Spondylitis with Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711674
DOI https://dx.doi.org/10.2174/187152310790711674 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared
Drug Metabolism Letters Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews Detection of Damaging nsSNPs on Human Caspase-Cascades Related to Apoptotic Signalling Pathway
Protein & Peptide Letters Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Current Molecular Medicine JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry Editorial [Hot topic: Ocular Immunology (Guest Editor: Gerhild Wildner)]
Current Immunology Reviews (Discontinued) The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn´s Disease
Current Medicinal Chemistry Measures in Musculoskeletal Ultrasound. What are Valid?
Current Rheumatology Reviews Features of Undifferentiated Spondyloarthropathy and Juvenile Spondyloarthropathy Among Asian Populations
Current Rheumatology Reviews Musculoskeletal US: Taking the Management of Psoriatic Arthritis to a New Horizon
Current Rheumatology Reviews Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design The Biology of p38 Kinase: A Central Role in Inflammation
Current Topics in Medicinal Chemistry There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets